Clinical Trial Update: ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of ExoFlo Infusion for post-acute COVID-19 and chronic post-COVID-19 syndrome has been withdrawn by the sponsor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyspnea
• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• ExoFlo

Snippet

Sponsor: Direct Biologics, LLC | Conditions: Covid19, Postviral Syndrome | Phase 1, Phase 2 | Status: WITHDRAWN